<DOC>
	<DOC>NCT02075008</DOC>
	<brief_summary>This study will assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.</brief_summary>
	<brief_title>Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201</brief_title>
	<detailed_description>This study will assess long-term safety and tolerability of QGE031 administered every 4 weeks for an additional 12 months in patients with allergic asthma who previously completed study CQGE031B2201.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Key forced Expiratory Volume in one second ( FEV1) &gt; 40% predicted patients who completed CQGE031B2201 study Key lifethreatening asthma attack, intubation, respiratory arrest during or after completion of CQGE031B2201 study new malignancy ongoing SAE from CQGE031B2201 that was assessed as related to study drug patient experienced platelets drop to &lt; 75,000/uL patient experienced one unexpected grade 4 or two unexpected grade 3 hypersensitivity reactions patient is pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>allergic asthma</keyword>
	<keyword>QGE031</keyword>
	<keyword>open-label</keyword>
	<keyword>IgE</keyword>
	<keyword>long-term safety</keyword>
</DOC>